Clinical trials: Steatosis
Nonalcoholic Fatty Liver Disease
Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD
This is a randomised clinical trial which aims to evaluate the efficacy of Compound Zhenzhu Tiaozhi capsules in the treatment of NAFLD and analyze the relationship between improvement in NAFLD parameters and changes in intestinal…
- Trial name
- NCT03375580
- Testing
- TLC, metformin, Compound Zhenzhu Tiaozhi capsule
- Where
- China
- Volunteers
- 196 people
- Sponsor
- The First Affiliated Hospital of Guangdong Pharmaceutical University
Nonalcoholic Steatohepatitis, Liver Diseases
Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
The purpose of this study is to explore the potential benefit of the medication, pentoxifylline, for the treatment of NASH.
- Trial name
- NCT00267670
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northwestern University
Non-Alcoholic Fatty Liver Disease
Investigation on Safety and Efficacy of Soybean Fermented Extract (MBS217) in Treating Patients With NAFLD
Investigators aimed to investigate the efficacy and safety of fermented soybean extract (MBS-217) in treating participants with Non-alcoholic fatty liver disease (NAFLD) in this study.
- Trial name
- NCT05686174
- Testing
- MBS217
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
NASH, MASH
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks.
- Conditions
- NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
- Trial name
- HERALD (NCT06342947)
- Testing
- ALG-055009
- Where
- 40 sites in United States
- Volunteers
- 102 people
- Sponsor
- Aligos Therapeutics
Non-Alcoholic Fatty Liver Disease
Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population and causes serious complications, including cirrhosis, hepatocellular carcinoma or mortality.
- Trial name
- NCT05754385
- Testing
- Ambulatory monitoring of liver fat, Standard of care
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The University of Hong Kong
Insulin Resistance, Hyperinsulinemia
Effect of Alpelisib in Healthy Volunteers
The goal of this clinical trial is to test a single dose of the phosphoinositide-3-kinase (PI3K) inhibitor alpelisib versus placebo in healthy volunteers.
- Conditions
- Insulin Resistance, Hyperinsulinemia, Dyslipidemias
- Trial name
- NCT05733455
- Testing
- Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Columbia University
Nonalcoholic Steatohepatitis
Betaine in Patients With Nonalcoholic Steatohepatitis
To assess the safety and efficacy of betaine in patients with NASH on markers of disease severity such as liver histology, liver biochemistries, and health related quality of life.
- Trial name
- NCT00586911
- Testing
- Cystadane
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
Nonalcoholic Fatty Liver Disease, Metabolic-associated Fatty Liver Disease
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease.
- Trial name
- NCT07149571
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Hyperlipidemia, NAFLD
Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
This study will investigate the efficacy, safety, and tolerability of VK2809 in lowering LDL-C and liver fat content in patients with primary hypercholesterolemia and fatty liver disease.
- Trial name
- NCT02927184
- Testing
- VK2809
- Where
- 19 sites in United States
- Volunteers
- 59 people
- Sponsor
- Viking Therapeutics, Inc.
Prediabetes, Diabetes Mellitus Type 2
Diabetes Nutrition Algorithm - Prediabetes
Prediabetes, defined by either impaired fasting glucose and/or impaired glucose tolerance, is a known high-risk condition predisposing to future diabetes mellitus type 2.
- Conditions
- Prediabetes, Diabetes Mellitus Type 2, Obesity, NAFLD
- Trial name
- DiNA-P (NCT02609243)
- Testing
- dietary consulting
- Where
- 2 sites in Germany
- Volunteers
- 250 people
- Sponsor
- German Institute of Human Nutrition
Chronic Hepatitis b, Non-Alcoholic Fatty Liver Disease
Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis
Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled.
- Trial name
- NCT05786963
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
NASH With Fibrosis
Non-alcoholic Steatohepatitis Registry Platform Study
This is a multi-center, prospective, observational registry platform study aimed at describing the clinical characteristics and diagnosis and treatment patterns of Chinese patients with nonalcoholic steatohepatitis (NASH) with…
- Trial name
- NCT06123858
- Where
- 16 sites in China
- Volunteers
- 1,122 people
- Sponsor
- AstraZeneca
Fatty Liver, Nonalcoholic
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
The aim of the current study is to evaluate the safety and efficay of cilostazol in treatment of patients with fatty liver disease. Several previous reports have shown that cilostazol ameliorates lipid imbalances in NAFLD.
- Trial name
- NCT04761848
- Testing
- Cilostazol 50 MG
- Where
- Egypt
- Sponsor
- Sadat City University
Fatty Liver
Resveratrol in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) and fatty liver hepatitis (NASH) are very common in the Western world and strongly associated with obesity. No known effective treatment is known.
- Trial name
- LIRMOI3 (NCT01464801)
- Testing
- Resveratrol
- Where
- Denmark
- Volunteers
- 28 people
- Sponsor
- University of Aarhus
Non-alcoholic Fatty Liver Disease
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
The objective of this study is to provide clinical data to support the effectiveness of a mixture of ingredients of natural origin, suitably selected and packaged, in the protection from liver damage, in subjects with NAFLD.
- Trial name
- NUTRAFAST (NCT02369536)
- Testing
- nutraceutical mixture
- Where
- Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Nonalcoholic Steatohepatitis (NASH)
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
An Open-Label Part was added: This part will enroll in selected sites which are less affected by the COVID-19 pandemic. 150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups…
- Trial name
- ARMOR (NCT04104321)
- Testing
- Aramchol free acid
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- Galmed Research and Development, Ltd.
Non-alcoholic Fatty Liver Disease
Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis.
- Trial name
- NCT02875392
- Testing
- 275mg Oligo Fucoidan + 275mg HS Fucoxanthin
- Where
- Taiwan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
NASH, NAFLD
Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease
The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, Metabolic dysfunction-associated steatohepatitis (MASH), is high and they are increasingly becoming major causes of…
- Trial name
- CALIBRE (NCT06879236)
- Where
- Italy
- Volunteers
- 252 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NAFLD
Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects
Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse.
- Trial name
- NCT05930093
- Testing
- 2 cap.LivPhcD/per day, 4 cap.LivPhcD/per day, 6 cap.LivPhcD/per day
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- TCM Biotech International Corp.
Metabolic Syndrome
Impact of Extra Virgin Olive Oil (EVOO) with Health Properties in Metabolic Syndrome
Metabolic syndrome (MS), defined according to the revised Adult Treatment Panel III - National Cholesterol Education Program (ATP III - NCEP) criteria, represents a widespread condition in Western populations (prevalence ranging…
- Trial name
- NCT05282316
- Testing
- EVOO polyphenols enriched, EVOO standard
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- University of Palermo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.